Camilla Mattiuzzi, MD is an expert in Hematology at Ospedale Santa Chiara (Italy). As of October 2025, ScienceLeadR ranks Camilla Mattiuzzi in the top 1% of experts worldwide for COVID-19, Coronavirus Infections and Pneumonia. Camilla Mattiuzzi has authored 274 publications, the most recent in 2025. SLR score: 769 (community average: 125). How the SLR is computed.

LeadR Profile

Camilla Mattiuzzi, MD Ospedale Santa Chiara Italy
769 ScienceLeadR Reputation 769
Network Map

Hematology

Subspecialties: Public Health - Infectiology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2016 - 2023

Source: PubMed

Ospedale Santa Chiara

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 274

Citations

Citations: 6 481 1st author: 92 Last author: 68 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Mortality trends for bacterial septicaemia in the United States (1999-2024): Age, sex disparities and the impact of the COVID-19 pandemic.
PMID 40967521 — regression analysis, mortality, aged, covid-19, sex, diagnosis, pandemics
Am J Med Sci20250
The increasing association of pulmonary embolism with cancer deaths: A seven-year, US-based, nationwide analysis.
PMID 40773809 — regression analysis, mortality, embolism, neoplasms, public health, pulmonary embolism
Public Health20250
Temporal Trends in Pulmonary Embolism Mortality Associated with COVID-19 in the United States: A 5-Year Retrospective Analysis.
PMID 40771291 — mortality, embolism, covid-19, pulmonary embolism, pandemics
Int J Angiol20250
Correction: Nocini et al. Improving Nasal Protection for Preventing SARS-CoV-2 Infection. Biomedicines 2022, 10, 2966.
PMID 40722860 — sars-cov-2, covid-19, severe acute respiratory syndrome-related coronavirus, infections
Biomedicines20250
A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes.
PMID 40647694 — diabetes mellitus, autoantibodies, antibodies, enzyme-linked immunosorbent assay, immunoassay, diabetes mellitus, type 1
Diagnostics (Basel)20250

LeadR Networks

Main global connection map